Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme
Authors
Keywords
-
Journal
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Volume 23, Issue 5, Pages 466-479
Publisher
Wiley
Online
2014-02-21
DOI
10.1002/pds.3554
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines
- (2013) Fernanda Tavares Da Silva et al. VACCINE
- Four-Year Follow-up of the Immunogenicity and Safety of the HPV-16/18 AS04-Adjuvanted Vaccine When Administered to Adolescent Girls Aged 10–14 Years
- (2012) Tino F. Schwarz et al. JOURNAL OF ADOLESCENT HEALTH
- Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine
- (2012) Cecilia M. Roteli-Martins et al. Human Vaccines & Immunotherapeutics
- Randomized Trial of the Immunogenicity and Safety of the Hepatitis B Vaccine Given in an Accelerated Schedule Coadministered with the Human Papillomavirus Type 16/18 AS04-Adjuvanted Cervical Cancer Vaccine
- (2011) Geert Leroux-Roels et al. Clinical and Vaccine Immunology
- Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years
- (2011) Tino F. Schwarz et al. Human vaccines & immunotherapeutics
- Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years
- (2011) Mark H. Einstein et al. Human vaccines & immunotherapeutics
- Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule
- (2011) Barbara Romanowski et al. Human vaccines & immunotherapeutics
- Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine
- (2011) Mark H. Einstein et al. Human vaccines & immunotherapeutics
- Randomized Trial: Immunogenicity and Safety of Coadministered Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine and Combined Hepatitis A and B Vaccine in Girls
- (2011) Court Pedersen et al. JOURNAL OF ADOLESCENT HEALTH
- Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine
- (2011) Aimée R. Kreimer et al. JNCI-Journal of the National Cancer Institute
- Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial
- (2011) Aimée R Kreimer et al. LANCET ONCOLOGY
- Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
- (2011) Cosette M Wheeler et al. LANCET ONCOLOGY
- Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-adjuvanted Vaccine Coadministered With Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and/or Meningococcal Conjugate Vaccine to Healthy Girls 11 to 18 Years of Age
- (2011) Cosette M. Wheeler et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: Randomized study in healthy girls
- (2011) Channa E. Schmeink et al. VACCINE
- The safety evaluation of adjuvants during vaccine development: The AS04 experience
- (2011) Nathalie Garçon et al. VACCINE
- Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica
- (2011) R. Herrero et al. Cancer Discovery
- Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials
- (2010) Dominique Descamps et al. Human vaccines & immunotherapeutics
- Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years
- (2010) Mark H. Einstein et al. Human vaccines & immunotherapeutics
- Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women
- (2010) Tiina Petäjä et al. INTERNATIONAL JOURNAL OF CANCER
- Efficacy of Human Papillomavirus Type 16/18 AS04-Adjuvanted Vaccine in Japanese Women Aged 20 to 25 Years
- (2010) Ryo Konno et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Could Autoimmunity Be Induced by Vaccination?
- (2010) Simonetta Salemi et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine: A Randomized, Controlled Trial in Adolescent Girls
- (2010) Doris M. Rivera Medina et al. JOURNAL OF ADOLESCENT HEALTH
- Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Cervical Cancer Vaccine Coadministered With Combined Diphtheria-Tetanus-Acellular Pertussis–inactivated Poliovirus Vaccine to Girls and Young Women
- (2010) José Garcia-Sicilia et al. JOURNAL OF ADOLESCENT HEALTH
- Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years
- (2010) Young-Jae Kim et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women
- (2010) Neerja Bhatla et al. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
- (2010) Silvia de Sanjose et al. LANCET ONCOLOGY
- Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women
- (2010) N. De Carvalho et al. VACCINE
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
- (2009) J Paavonen et al. LANCET
- The identification of pregnancies within the general practice research database
- (2009) Scott Devine et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines
- (2008) Thomas Verstraeten et al. VACCINE
- Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years
- (2008) Tino F. Schwarz et al. VACCINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now